US FDA Approves Novo Nordisk's Diabetes Drug to Reduce Risk of Worsening Kidney Disease
(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
Major heart health risk factors like obesity, diabetes and high blood pressure remain on the rise in the United States, ...
Robert F. Kennedy Jr., President Trump’s nominee for health secretary, doesn’t just hold fringe views on vaccines. We ...
A groundbreaking stem cell therapy offers new hope for type 1 diabetes, with early results showing potential for insulin ...
A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...
On average, the burden of sugar-sweetened beverage intake was higher among men than women, as well as among younger adults, ...
With continuous glucose monitors, students with Type 1 diabetes no longer have to visit the school nurse for a finger prick. But some parents say it falls to them to keep an eye on blood sugar levels ...
For patients with diabetes undergoing Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), overall expenditures ...
A recent study suggests that type 2 diabetes can be reversed through a combination of calorie reduction, physical activity, ...
Swelling of limbs, fatigue may not just be a sign of high blood sugar, but it may also affect your kidney health. Read on to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback